Repository logo
 
Publication

Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases

2018Journal article Restricted access
Simple item page
dc.contributor.authorCunha, S.
dc.contributor.authorAlmeida, H.
dc.contributor.authorAmaral, M.H.
dc.contributor.authorLobo, J.M. Sousa
dc.contributor.authorSilva, Ana Catarina
dc.date.accessioned2021-04-27T11:40:37Z
dc.date.available2021-04-27T11:40:37Z
dc.date.issued2018
dc.description.abstractBackground: treatments for neurodegenerative diseases are challenging, due to the absence of fully effective medicines. One of the major problems associated to these is the occurrence of non-targeting events, which leads to adverse effects and requires frequent dose administration. Methods: Researches have been performed to develop new drug delivery systems administrated by alternative routes. For example, the direct nose-to-brain delivery of drugs by means of lipid nanoparticles, such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC), has been showing promising results. Results: Among the advantages of intranasal administration is the avoidance of passing the blood-brain barrier (BBB) to reach the central nervous system (CNS), allowing the direct delivery of drugs to the brain by a noninvasive way, minimizing systemic exposure and prolonging residence time. This review article discusses the advantages of using SLN and NLC for direct nose-to-brain drug delivery. A brief reference to other lipid-based carriers (liposomes, nanoemulsions and microemulsions) is also provided. Conclusion: The benefits of using SLN and NLC for improve nasal drug delivery have been demonstrated by in vitro, ex vivo and in vivo experiments. However, more in vivo animal studies are needed for advance to human clinical trials and reach clinics.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.2174/1381612824666171128105305pt_PT
dc.identifier.issn1381-6128
dc.identifier.urihttp://hdl.handle.net/10284/9800
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBentham Science Publisherspt_PT
dc.subjectNasal/intranasal administrationpt_PT
dc.subjectNeurodegenerative diseasespt_PT
dc.subjectNose-to-brainpt_PT
dc.subjectNanostructured lipid carrierspt_PT
dc.subjectSolid lipid nanoparticlespt_PT
dc.subjectLiposomespt_PT
dc.subjectNanoemulsionspt_PT
dc.subjectMicroemulsionspt_PT
dc.titleIntranasal lipid nanoparticles for the treatment of neurodegenerative diseasespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage10pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleCurrent Pharmaceutical Designpt_PT
oaire.citation.volume23pt_PT
person.familyNameSilva
person.givenNameAna Catarina
person.identifier953153
person.identifier.ciencia-id5C1D-ED22-0D64
person.identifier.orcid0000-0001-6923-0232
person.identifier.ridF-1875-2017
person.identifier.scopus-author-id57028697500
rcaap.rightsrestrictedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication67e7f707-32ec-444a-a20d-a17f8e6e7c21
relation.isAuthorOfPublication.latestForDiscovery67e7f707-32ec-444a-a20d-a17f8e6e7c21

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Intranasal Lipid Nanoparticles for the Treatment of Neurodegenerative Diseases.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Download

Collections

FCS (DCF) - Artigos em Revistas Científicas Internacionais com Arbitragem Científica